Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline.

In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

Teen idol Bobby Sherman dies at 81 Sherman had four Top 10 hits on the Billboard Hot 100 chart: “Little Woman,” “Julie, Do Ya Love Me,” “Easy Come, Easy Go,” and “La La La (If I Had You).” ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...

Germany’s Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on the rise around the world.